Infections in Patients with Multiple Myeloma in the Era of High‐Dose Therapy and Novel Agents

Nucci, Marcio; Anaissie, Elias

doi:10.1086/605664

Cited by 347Multiple Myeloma Research and TreatmentsNeutropenia and Cancer InfectionsAntifungal resistance and susceptibility

Infections in Patients with Multiple Myeloma in the Era of High‐Dose Therapy and Novel Agents

Nucci, Marcio, Anaissie, Elias·2009·Clinical Infectious Diseases

DOI 10.1086/605664

Open this paper in CoChat — free account

Abstract

The introduction of stem cell transplantation and the novel anti-myeloma agents, bortezomib, thalidomide, and lenalidomide, have improved the outcome of patients with multiple myeloma. These advances have transformed myeloma into a chronic condition, with multiple relapses and salvage therapies, all of which result in cumulative immunosuppression and higher risk of infection. In addition to the immunodeficiency related to myeloma and its complications, the type of anti-myeloma therapy used also plays a role in the development of infection. Therapy with bortezomib increases the risk for reactivation of herpes simplex and herpes zoster viruses, whereas the application of stem cell transplantation has broadened the spectrum of infection to include those caused by Clostridium difficile, cytomegalovirus, and opportunistic moulds. Key to the management of infection is the understanding of the specific risk factors and periods during which patients are at risk; this allows the anticipation of the likely pathogen(s) and the application of risk-adjusted prophylactic and treatment strategies.

Integrity signals

Registry

Crossref · 10.1086/605664

Cites

118 of 118 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Adverse events in this trial were common and included low-grade cytokine release syndrome and grade 3 or 4 cytopenia and infection in a patient population with increased susceptibility to infection due to myeloma-associated immunodeficiency and immunosuppressive effects of previous therapies.
“Adverse events in this phase 1–2 trial were common and included low-grade cytokine release syndrome and grade 3 or 4 cytopenia and infection in a patient population that has an increased susceptibility to infection due to the immunodeficiency associated with myeloma and immunosuppressive effects of previous myeloma therapies.23”
From Teclistamab in Relapsed or Refractory Multiple Myeloma (2022) · cites this paper as [23]

Bortezomib or High-Dose Dexamethasone for Relapsed Multiple Myeloma
Richardson, P. G. G., Sonneveld, P., Schuster, M. W., Irwin, D. H., Stadtmauer, E. A., Facon, T. T. F., Harousseau, J., Ben‐Yehuda, D., Lonial, S., Goldschmidt, H., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043445 · Cited by 2,488 · see citing works
Bortezomib plus Melphalan and Prednisone for Initial Treatment of Multiple Myeloma
San Miguel, J. F., Schlag, R., Khuageva, N. K., Dimopoulos, M. A., Shpilberg, O., Kropff, M., Spicka, I., Petrucci, M. T., Palumbo, A., Samoilova, O. S., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0801479 · Cited by 1,899 · see citing works
The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells.
Hideshima, T., Richardson, P. G. G., Chauhan, D., Palombella, V. J., Elliott, P. J., Adams, J., & Anderson, K. C. (2001) · PubMed · Cited by 1,518 · see citing works
Lenalidomide plus Dexamethasone for Relapsed or Refractory Multiple Myeloma
Dimopoulos, M., Spencer, A., Attal, M., Prince, H. M., Harousseau, J.-L., Dmoszynska, A., Miguel, J. S., Hellmann, A., Facon, T., Foà, R., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa070594 · Cited by 1,450 · see citing works
Epidemiology and Outcome of Mould Infections in Hematopoietic Stem Cell Transplant Recipients
Marr, K. A., Carter, R. A., Crippa, F., Wald, A., & Corey, L. (2002) · Clinical Infectious Diseases · doi:10.1086/339202 · Cited by 1,446 · see citing works
Lenalidomide plus Dexamethasone for Relapsed Multiple Myeloma in North America
Weber, D. M., Chen, C., Niesvizky, R., Wang, M., Belch, A., Stadtmauer, E. A., Siegel, D., Borrello, I., Rajkumar, S. V., Chanan-Khan, A. A., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa070596 · Cited by 1,233 · see citing works
Natural History and Outcome in Systemic AA Amyloidosis
Lachmann, H. J., Goodman, H. J. B., Gilbertson, J. A., Gallimore, J. R., Sabin, C. A., Gillmore, J. D., & Hawkins, P. N. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa070265 · Cited by 1,025 · see citing works
Antiviral drugs in current clinical use
Clercq, E. D. (2004) · Journal of Clinical Virology · doi:10.1016/j.jcv.2004.02.009 · Cited by 952 · see citing works
Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma
Davies, F. E., Raje, N. S., Hideshima, T., Lentzsch, S., Young, G. Q., Tai, Y., Lin, B. K., Podar, K., Gupta, D., Chauhan, D., et al. (2001) · Blood · doi:10.1182/blood.v98.1.210 · Cited by 912 · see citing works
Pharmacokinetics and pharmacodynamics of systemically administered glucocorticoids.
Czock, D., Keller, F., Rasche, F. M., & H??ussler, U. (2005) · Clinical Pharmacokinetics · doi:10.2165/00003088-200544010-00003 · Cited by 886 · see citing works
Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99–06): a randomised trial
Facon, T. T. F., Mary, J., Hulin, C., Benboubker, L., Attal, M., Pegourié, B., Renaud, M., Harousseau, J. L., Guillerm, G., Chaleteix, C., et al. (2007) · The Lancet · doi:10.1016/s0140-6736(07)61537-2 · Cited by 865 · see citing works
Phase III Clinical Trial of Thalidomide Plus Dexamethasone Compared With Dexamethasone Alone in Newly Diagnosed Multiple Myeloma: A Clinical Trial Coordinated by the Eastern Cooperative Oncology Group
Rajkumar, S. V., Blood, E., Vesole, D., Fonseca, R., & Greipp, P. R. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.03.0221 · Cited by 865 · see citing works
Multiple Myeloma: Diagnosis and Treatment
Rajkumar, S. V., & Kumar, S. (2016) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2015.11.007 · Cited by 812 · see citing works
Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial
Palumbo, A., Bringhen, S., Caravita, T., Merla, E., Capparella, V., Callea, V., Cangialosi, C., Grasso, M., Rossini, F., Galli, M., et al. (2006) · The Lancet · doi:10.1016/s0140-6736(06)68338-4 · Cited by 806 · see citing works
Thalidomide and Hematopoietic-Cell Transplantation for Multiple Myeloma
Barlogie, B., Tricot, G. J. K., Anaissie, E. J., Shaughnessy, J. D., Rasmussen, E., van Rhee, F., Fassas, A., Zangari, M., Hollmig, K. A., Pineda‐Roman, M., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa053583 · Cited by 736 · see citing works
Self-citation
Oral Mucositis and the Clinical and Economic Outcomes of Hematopoietic Stem-Cell Transplantation
Sonis, S. T., Oster, G., Fuchs, H., Bellm, L. A., Bradford, W. Z., Edelsberg, J., Hayden, V., Eilers, J., Epstein, J. B., LeVeque, F. G., et al. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.8.2201 · Cited by 679 · see citing works
Combination therapy with lenalidomide plus dexamethasone (Rev/Dex) for newly diagnosed myeloma
Rajkumar, S. V., Hayman, S. R., Lacy, M. Q., Dispenzieri, A., Geyer, S. M., Kabat, B., Zeldenrust, S. R., Kumar, S., Greipp, P. R., Fonseca, R., et al. (2005) · Blood · doi:10.1182/blood-2005-07-2817 · Cited by 648 · see citing works
Guidelines for preventing opportunistic infections among hematopoietic stem cell transplant recipients
(2000) · Transplantation and Cellular Therapy · doi:10.1016/s1083-8791(00)70002-4 · Cited by 607 · see citing works
Osteonecrosis of the Jaw in Multiple Myeloma Patients: Clinical Features and Risk Factors
Badros, A. Z., Weikel, D. S., Salama, A., Goloubeva, O. G., Schneider, A., Rapoport, A. P., Fenton, R. G., Gahres, N., Sausville, E. A., Ord, R. A., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.2465 · Cited by 583 · see citing works
Thalidomide Costimulates Primary Human T Lymphocytes, Preferentially Inducing Proliferation, Cytokine Production, and Cytotoxic Responses in the CD8+ Subset
Haslett, P. A. J., Corral, L. G., Albert, M. L., & Kaplan, G. (1998) · The Journal of Experimental Medicine · doi:10.1084/jem.187.11.1885 · Cited by 572 · see citing works
A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma
Richardson, P. G., Blood, E., Mitsiades, C. S., Jagannath, S., Zeldenrust, S. R., Alsina, M., Schlossman, R. L., Rajkumar, S. V., Desikan, K. R., Hideshima, T., et al. (2006) · Blood · doi:10.1182/blood-2006-04-015909 · Cited by 523 · see citing works
Meta-Analysis: Antibiotic Prophylaxis Reduces Mortality in Neutropenic Patients
Gafter‐Gvili, A., Fraser, A., Paul, M., & Leibovici, L. (2005) · Annals of Internal Medicine · doi:10.7326/0003-4819-142-12_part_1-200506210-00008 · Cited by 495 · see citing works
Increased risk of deep-vein thrombosis in patients with multiple myeloma receiving thalidomide and chemotherapy
Zangari, M., Anaissie, E. J., Barlogie, B., Badros, A. Z., Desikan, R. K., Gopal, A. V., Morris, C., Toor, A. A., Siegel, E. R., Fink, L. M., et al. (2001) · Blood · doi:10.1182/blood.v98.5.1614 · Cited by 490 · see citing works
Self-citation
Early Mortality After Diagnosis of Multiple Myeloma: Analysis of Patients Entered Onto the United Kingdom Medical Research Council Trials Between 1980 and 2002—Medical Research Council Adult Leukaemia Working Party
Augustson, B. M., Begum, G., Dunn, J., Barth, N. J., Davies, F. E., Morgan, G. J., Behrens, J., Smith, A. G., Child, J. A., & Drayson, M. T. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.03.2086 · Cited by 486 · see citing works
Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: results of a multicenter phase 1/2 study
Mateos, M., Hernández, J., Hernández, M.-T., Gutierrez, N. C., Palomera, L., Fuertes, M., Diaz‐Mediavilla, J., Lahuerta, J. J., de la Rubia, J., Terol, M. J., et al. (2006) · Blood · doi:10.1182/blood-2006-04-019778 · Cited by 387 · see citing works
Dendritic cells from patients with myeloma are numerically normal but functionally defective as they fail to up-regulate CD80 (B7-1) expression after huCD40LT stimulation because of inhibition by transforming growth factor-β1 and interleukin-10
Brown, R. D., Pope, B., Murray, A., Esdale, W., Sze, D., Gibson, J., Ho, P. J., Hart, D. N. J., & Joshua, D. (2001) · Blood · doi:10.1182/blood.v98.10.2992 · Cited by 346 · see citing works
Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of Thalidomide Plus Dexamethasone Compared With Dexamethasone As Initial Therapy for Newly Diagnosed Multiple Myeloma
Rajkumar, S. V., Rosiñol, L., Hussein, M. A., Catalano, J. V., Wiktor-Jędrzejczak, W., Lucy, L. M., Olesnyckyj, M., Yu, Z., Knight, R., Zeldis, J. B., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.1853 · Cited by 341 · see citing works
Melphalan, Prednisone, and Lenalidomide Treatment for Newly Diagnosed Myeloma: A Report From the GIMEMA—Italian Multiple Myeloma Network
Palumbo, A. P., Falco, P., Corradini, P., Falcone, A. P., Raimondo, F. D., Giuliani, N., Crippa, C., Ciccone, G., Omedè, P., Ambrosini, M. T., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.12.3463 · Cited by 317 · see citing works
Oral chelators deferasirox and deferiprone for transfusional iron overload in thalassemia major: new data, new questions
Neufeld, E. J. (2006) · Blood · doi:10.1182/blood-2006-02-002394 · Cited by 317 · see citing works
Use of an Inactivated Varicella Vaccine in Recipients of Hematopoietic-Cell Transplants
Hata, A., Asanuma, H., Rinki, M., Sharp, M., Wong, R. M., Blume, K. G., & Arvin, A. M. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa013441 · Cited by 300 · see citing works
Clinical pharmacology of thalidomide
Eriksson, T., Björkman, S. E., & Höglund, P. (2001) · European Journal of Clinical Pharmacology · doi:10.1007/s002280100320 · Cited by 298 · see citing works
Bisphosphonate-induced osteonecrosis of the jaws: Prospective study of 80 patients with multiple myeloma and other malignancies
Boonyapakorn, T., Schirmer, I., Reichart, P. A., Sturm, I., & Massenkeil, G. (2008) · Oral Oncology · doi:10.1016/j.oraloncology.2007.11.012 · Cited by 278 · see citing works
Analysis of Herpes Zoster Events Among Bortezomib-Treated Patients in the Phase III APEX Study
Chanan-Khan, A. A., Sonneveld, P., Schuster, M. W., Stadtmauer, E. A., Facon, T. T. F., Harousseau, J., Ben‐Yehuda, D., Lonial, S., Goldschmidt, H., Reece, D. E., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.9641 · Cited by 262 · see citing works
Randomised trial of intravenous immunoglobulin as prophylaxis against infection in plateau-phase multiple myeloma
Chapel, H. M., Lee, M., Hargreaves, R., Pamphilon, D. H., Prentice, A., Chapel, H. M., Hargreaves, R., Lee, M., Pamphilon, D. H., & Prentice, A. (1994) · The Lancet · doi:10.1016/s0140-6736(94)90180-5 · Cited by 258 · see citing works
Recent advances in understanding the mechanism of action of bisphosphonates
Coxon, F. P., Thompson, K., & Rogers, M. J. (2006) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2006.03.005 · Cited by 254 · see citing works
Pharmacokinetics of Lenalidomide in Subjects With Various Degrees of Renal Impairment and in Subjects on Hemodialysis
Chen, N., Lau, H. S. H., Kong, L., Kumar, G. N., Zeldis, J. B., Knight, R., & Laskin, O. L. (2007) · The Journal of Clinical Pharmacology · doi:10.1177/0091270007309563 · Cited by 248 · see citing works
Inhibition of acute graft-versus-host disease with retention of graft-versus-tumor effects by the proteasome inhibitor bortezomib
Sun, K., Welniak, L. A., Panoskaltsis‐Mortari, A., O’Shaughnessy, M. J., Liu, H., Barão, I., Riordan, W., Sitcheran, R., Wysocki, C., Serody, J. S., et al. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0401563101 · Cited by 245 · see citing works
Canadian consensus practice guidelines for bisphosphonate associated osteonecrosis of the jaw.
Khan, A. A., Sándor, G. K. B., Dore, E., Morrison, A. D., Alsahli, M., Amin, F., Peters, E., Hanley, D. A., CHAUDRY, S. R., Dempster, D. W., et al. (2008) · PubMed · Cited by 204 · see citing works
Safety and tolerability of linezolid
French, G. L. (2003) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkg253 · Cited by 204 · see citing works
Immunomodulation by thalidomide and thalidomide analogues
Corral, L. G., & Kaplan, G. (1999) · Annals of the Rheumatic Diseases · doi:10.1136/ard.58.2008.i107 · Cited by 202 · see citing works
Immunogenicity of vaccination against influenza, Streptococcus pneumoniae and Haemophilus influenzae type B in patients with multiple myeloma
Robertson, J. D., Nagesh, K., Jowitt, S., Dougal, M., Anderson, H., Mutton, K. J., Zambon, M. C. F. A., & Scarffe, J. H. (2000) · British Journal of Cancer · doi:10.1054/bjoc.1999.1088 · Cited by 198 · see citing works
Bortezomib induces selective depletion of alloreactive T lymphocytes and decreases the production of Th1 cytokines
Blanco, B., Pérez‐Simón, J. A., Sánchez-Abarca, L. I., Carvajal‐Vergara, X., Mateos, J. J. N., Vídriales, M., López-Holgado, N., Maiso, P., Alberca, M., Villarón, E. M., et al. (2005) · Blood · doi:10.1182/blood-2005-05-2118 · Cited by 193 · see citing works
Engraftment syndrome following autologous hematopoietic stem cell transplantation: definition of diagnostic criteria
Maiolino, Â., Biasoli, I., Lima, J., Portugal, A., Pulcheri, W., & Nucci, M. (2003) · Bone Marrow Transplantation · doi:10.1038/sj.bmt.1703855 · Cited by 185 · see citing works
Self-citation
Properties of thalidomide and its analogues: Implications for anticancer therapy
Teo, S. K. O. (2005) · The AAPS Journal · doi:10.1208/aapsj070103 · Cited by 184 · see citing works
BiRD (Biaxin [clarithromycin]/Revlimid [lenalidomide]/dexamethasone) combination therapy results in high complete- and overall-response rates in treatment-naive symptomatic multiple myeloma.
Niesvizky, R., Jayabalan, D. S., Christos, P. J., Furst, J. R., Naib, T., Ely, S. A., Jalbrzikowski, J., Pearse, R. N., Zafar, F., Pekle, K. A., et al. (2007) · Blood · doi:10.1182/blood-2007-05-090258 · Cited by 184 · see citing works
Bortezomib, melphalan, prednisone, and thalidomide for relapsed multiple myeloma
Palumbo, A., Ambrosini, M. T., Benevolo, G., Pregno, P., Pescosta, N., Callea, V., Cangialosi, C., Caravita, T., Morabito, F., Musto, P., et al. (2006) · Blood · doi:10.1182/blood-2006-08-042275 · Cited by 181 · see citing works
Major Complications following Hematopoietic Stem Cell Transplantation
Afessa, B., & Peters, S. G. (2006) · Seminars in Respiratory and Critical Care Medicine · doi:10.1055/s-2006-945530 · Cited by 181 · see citing works
Dexamethasone-based regimens versus melphalan-prednisone for elderly multiple myeloma patients ineligible for high-dose therapy
Facon, T. T. F. (2005) · Blood · doi:10.1182/blood-2005-04-1588 · Cited by 180 · see citing works
Lenalidomide plus dexamethasone is more effective than dexamethasone alone in patients with relapsed or refractory multiple myeloma regardless of prior thalidomide exposure
Wang, M., Dimopoulos, M. A., Chen, C., Cibeira, M. T., Attal, M., Spencer, A., Rajkumar, S. V., Yu, Z., Olesnyckyj, M., Zeldis, J. B., et al. (2008) · Blood · doi:10.1182/blood-2008-02-141614 · Cited by 176 · see citing works
Comprehensive Geriatric assessment and its clinical impact in oncology
Maas, H. A. A. M., Janssen-Heijnen, M. L. G., Rikkert, M. G. M. O., & Wymenga, A. N. M. (2007) · European Journal of Cancer · doi:10.1016/j.ejca.2007.08.002 · Cited by 172 · see citing works
Natural resistance, iron and infection: a challenge for clinical medicine
Bullen, J. J., Rogers, H. J., Spalding, P. B., & Ward, C. G. (2006) · Journal of Medical Microbiology · doi:10.1099/jmm.0.46386-0 · Cited by 163 · see citing works
The oral combination of thalidomide, cyclophosphamide and dexamethasone (ThaCyDex) is effective in relapsed/refractory multiple myeloma
García‐Sánz, R., González‐Porras, J. R., Hernández‐Rivas, J. M., Zarzuela, M. P., Sureda, A. M., Barrenetxea, C., Palomera, L., López, R., García, C. G., Alegre, A. M., et al. (2004) · Leukemia · doi:10.1038/sj.leu.2403322 · Cited by 159 · see citing works
Thalidomide and its analogues have distinct and opposing effects on TNF-αand TNFR2 during co-stimulation of both CD4+ and CD8+ T cells
Marriott, J. B., Clarke, I., Dredge, K. S., Muller, G. W., Stirling, D., & Dalgleish, A. G. (2002) · Clinical & Experimental Immunology · doi:10.1046/j.1365-2249.2002.01954.x · Cited by 155 · see citing works
Infectious Complications of Indwelling Long-term Central Venous Catheters
Clarke, D. E., & Raffin, T. A. (1990) · CHEST Journal · doi:10.1378/chest.97.4.966 · Cited by 152 · see citing works
Biphasic Pattern of Bacterial Infection in Multiple Myeloma
Savage, D. G., LINDENBAUM, J., & GARRETT, T. J. (1982) · Annals of Internal Medicine · doi:10.7326/0003-4819-96-1-47 · Cited by 144 · see citing works
Iron overload and immunity.
Porto, G. (2007) · World Journal of Gastroenterology · doi:10.3748/wjg.v13.i35.4707 · Cited by 140 · cited 1× · see citing works
“Conditioning regimen for HCT, post-engraftment Decrease in CMI, very severe in allogeneic HCT if severe GVHD [33] HSV, VZV, CMV, PJP; aspergillosis and other moulds in allogeneic HCT TPM-SMX prophylaxis for PJP; if severe GVHD, monitor serum CMV by PCR or antigenemia, Aspergillus galactomannan antigen Iron overload [3…”
Abnormal monoclonal antibody‐defined helper/suppressor T‐cell subpopulations in multiple myeloma: relationship to treatment and clinical stage
Mills, K. H. G., & Cawley, J. (1983) · British Journal of Haematology · doi:10.1111/j.1365-2141.1983.tb02021.x · Cited by 130 · see citing works
Proteasome inhibitor bortezomib modulates TLR4-induced dendritic cell activation
Nencioni, A., von Schwarzenberg, K., Brauer, K. M., Schmidt, S. M., Ballestrero, A., Grünebach, F., & Brossart, P. (2006) · Blood · doi:10.1182/blood-2005-08-3494 · Cited by 130 · see citing works
Frequent severe liver iron overload after stem cell transplantation and its possible association with invasive aspergillosis
Altés, A., Remacha, A. F., Sardà, P., Sancho, F. J., Sureda, A. M., Martino, R., Briones, J., Brunet, S., Canals, C., & Sierra, J. (2004) · Bone Marrow Transplantation · doi:10.1038/sj.bmt.1704628 · Cited by 129 · see citing works
Influence of Pretransplantation Serum Ferritin on Nonrelapse Mortality after Myeloablative and Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation
Kataoka, K., Nannya, Y., Hangaishi, A., Imai, Y., Chiba, S., Takahashi, T., & Kurokawa, M. (2009) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2008.11.012 · Cited by 129 · see citing works
Prophylactic antibiotics for the prevention of early infection in multiple myeloma
Oken, M. M., Pomeroy, C., Weisdorf, D. J., & Bennett, J. M. (1996) · The American Journal of Medicine · doi:10.1016/s0002-9343(95)00043-7 · Cited by 128 · see citing works
Autologous stem cell transplantation in multiple myeloma: outcome in patients with renal failure
Knudsen, L. M., Nielsen, B., Gimsing, P., & Geisler, C. H. (2005) · European Journal Of Haematology · doi:10.1111/j.1600-0609.2005.00446.x · Cited by 125 · see citing works
Bortezomib, doxorubicin and dexamethasone in advanced multiple myeloma
Palumbo, A., Gay, F., Bringhen, S., Falcone, A. P., Pescosta, N., Callea, V., Caravita, T., Morabito, F., Magarotto, V., Ruggeri, M., et al. (2008) · Annals of Oncology · doi:10.1093/annonc/mdn018 · Cited by 124 · see citing works
Immune parameters in multiple myeloma patients: influence of treatment and correlation with opportunistic infections
Schütt, P., Brandhorst, D., Stellberg, W., Poser, M., Ebeling, P. R., Müller, S., Buttkereit, U., Opalka, B., Lindemann, M., Grosse‐Wilde, H., et al. (2006) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428190500472503 · Cited by 123 · see citing works
Iron overload is a major risk factor for severe infection after autologous stem cell transplantation: a study of 367 myeloma patients
Miceli, M. H., Dong, L., Grazziutti, M., Fassas, A., Thertulien, R., van Rhee, F., Barlogie, B., & Anaissie, E. J. (2006) · Bone Marrow Transplantation · doi:10.1038/sj.bmt.1705340 · Cited by 122 · see citing works
Self-citation
Influence of treatment and response status on infection risk in multiple myeloma
Perri, R. T., Hebbel, R. P., & Oken, M. M. (1981) · The American Journal of Medicine · doi:10.1016/0002-9343(81)90303-x · Cited by 117 · see citing works
Secondary antifungal prophylaxis with voriconazole to adhere to scheduled treatment in leukemic patients and stem cell transplant recipients
Cordonnier, C., Maury, S., Pautas, C., Bastié, J. N., Chehata, S., Castaigné, S., Kuentz, M., Bretagne, S., & Ribaud, P. (2004) · Bone Marrow Transplantation · doi:10.1038/sj.bmt.1704469 · Cited by 116 · see citing works
Aerosolized pentamidine as pneumocystis prophylaxis after bone marrow transplantation is inferior to other regimens and is associated with decreased survival and an increased risk of other infections
Vasconcelles, M. J., Bernardo, M. P., King, C., Weller, E. A., & Antin, J. H. (2000) · Transplantation and Cellular Therapy · doi:10.1016/s1083-8791(00)70050-4 · Cited by 116 · see citing works
Pathophysiology of Posttraumatic Osteomyelitis
Tsukayama, D. T. (1999) · Clinical Orthopaedics and Related Research · doi:10.1097/00003086-199903000-00005 · Cited by 113 · see citing works
Vaccination of patients with haematological malignancies with one or two doses of influenza vaccine: a randomised study
Ljungman, P. T., Nahi, H., & Linde, A. (2005) · British Journal of Haematology · doi:10.1111/j.1365-2141.2005.05582.x · Cited by 109 · see citing works
Thalidomide and Deep Vein Thrombosis in Multiple Myeloma: Risk Factors and Effect on Survival
Zangari, M., Barlogie, B., Thertulien, R., Jacobson, J. L., Eddleman, P., Fink, L. M., Fassas, A., van Rhee, F., Talamo, G., Lee, C.-K., et al. (2003) · Clinical Lymphoma · doi:10.3816/clm.2003.n.011 · Cited by 108 · see citing works
Neuraminidase inhibitor resistance in influenza viruses
Reece, P. A. (2007) · Journal of Medical Virology · doi:10.1002/jmv.20951 · Cited by 93 · see citing works
Thalidomide and a Thalidomide Analogue Drug Costimulate Virus‐Specific CD8+T Cells In Vitro
Haslett, P. A. J., Hanekom, W. A., Muller, G. W., & Kaplan, G. (2003) · The Journal of Infectious Diseases · doi:10.1086/368126 · Cited by 91 · see citing works
Perspectives in Multiple Myeloma: Survival, Prognostic Factors and Disease Complications in a Single Centre Between 1975 and 1988
RAYNER, H., Haynes, A. P., Thompson, J., Russell, N. H., & FLETCHER, J. (1991) · QJM · doi:10.1093/oxfordjournals.qjmed.a068572 · Cited by 85 · see citing works
High Th1/Th2 ratio in patients with multiple myeloma
Ogawara, H., Handa, H., Yamazaki, T., Toda, T., Yoshida, K., Nishimoto, N., Al-ma’Quol, W. H. S., Kaneko, Y., Matsushima, T., Tsukamoto, N., et al. (2004) · Leukemia Research · doi:10.1016/j.leukres.2004.06.003 · Cited by 84 · see citing works
Safety and Tolerability of Oseltamivir Prophylaxis in Hematopoietic Stem Cell Transplant Recipients: A Retrospective Case-Control Study
Vu, D., Peck, A. J., Nichols, W. G., Varley, C. D., Englund, J. A., Corey, L., & Boeckh, M. (2007) · Clinical Infectious Diseases · doi:10.1086/518985 · Cited by 83 · see citing works
A randomised comparison of melphalan with prednisone or dexamethasone as induction therapy and dexamethasone or observation as maintenance therapy in multiple myeloma: NCIC CTG MY.7
Shustik, C., Belch, A. R., Robinson, S., Rubin, S. H., Dolan, S., Kovacs, M. J., Grewal, K. S., Walde, D., Barr, R., Wilson, J., et al. (2006) · British Journal of Haematology · doi:10.1111/j.1365-2141.2006.06405.x · Cited by 82 · see citing works
Low‐energy laser therapy for prevention of oral mucositis in hematopoietic stem cell transplantation
Jaguar, G., Prado, J., Nishimoto, I., Pinheiro, M., Castro, D. D., Pérez, D. E. D. C., & Alves, F. A. (2007) · Oral Diseases · doi:10.1111/j.1601-0825.2006.01330.x · Cited by 82 · see citing works
Candida oral colonization and infection in Brazilian patients undergoing head and neck radiotherapy: A pilot study
Jham, B. C., França, E. D. C., Oliveira, R. R., Santos, V. R., Kowalski, L. P., & Freire, A. R. D. S. (2006) · Oral Surgery Oral Medicine Oral Pathology Oral Radiology and Endodontology · doi:10.1016/j.tripleo.2006.02.005 · Cited by 69 · see citing works
Proteasome inhibitor‐induced apoptosis in human monocyte‐derived dendritic cells
Nencioni, A., Garuti, A., von Schwarzenberg, K., Cirmena, G., Bello, M. G. D., Rocco, I., Barbieri, E., Brossart, P., Patrone, F., & Ballestrero, A. (2006) · European Journal of Immunology · doi:10.1002/eji.200535298 · Cited by 68 · see citing works
Incidence of multiple myeloma in Olmsted County, Minnesota: 1978 through 1990, with a review of the trend since 1945.
Kyle, R. A., Beard, C. M., O’Fallon, W. M., & Kurland, L. T. (1994) · Journal of Clinical Oncology · doi:10.1200/jco.1994.12.8.1577 · Cited by 67 · see citing works
Bortezomib and the Increased Incidence of Herpes Zoster in Patients with Multiple Myeloma
Kim, S. J., Kım, K., Kim, B., Lee, H. J., Kim, H., Lee, N.-R., Nam, S.-H., Kwon, J. H., Kim, H. J., Sohn, S. K., et al. (2008) · Clinical Lymphoma & Myeloma · doi:10.3816/clm.2008.n.031 · Cited by 65 · see citing works
Oral cryotherapy reduces mucositis and opioid use after myeloablative therapy—a randomized controlled trial
Svanberg, A., Birgegård, G., & Öhrn, K. (2007) · Supportive Care in Cancer · doi:10.1007/s00520-007-0245-8 · Cited by 64 · see citing works
Randomized trial of lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone in newly diagnosed myeloma (E4A03), a trial coordinated by the Eastern Cooperative Oncology Group: Analysis of response, survival, and outcome wi
Rajkumar, S. V., Jacobus, S. J., Callander, N. S., Fonseca, R., Vesole, D. H., Williams, M. V., Abonour, R., Siegel, D. S. D., Katz, M. H. G., & Greipp, P. R. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.26.15_suppl.8504 · Cited by 62 · see citing works
Intravenous melphalan, thalidomide and prednisone in refractory and relapsed multiple myeloma
Palumbo, A., Avonto, I., Bruno, B., Ambrosini, M. T., Bringhen, S., Cavallo, F., Falco, P., & Boccadoro, M. (2006) · European Journal Of Haematology · doi:10.1111/j.1600-0609.2005.00610.x · Cited by 58 · see citing works
The Treatment of Relapsed and Refractory Multiple Myeloma
Richardson, P. G. G., Mitsiades, C. S., Schlossman, R. L., Ghobrial, I. M., Hideshima, T., Chauhan, D., Munshi, N. C., & Anderson, K. C. (2007) · Hematology · doi:10.1182/asheducation-2007.1.317 · Cited by 58 · see citing works
The burden of herpes zoster and postherpetic neuralgia in the United States.
Weaver, B. A. (2007) · PubMed · Cited by 57 · see citing works
A Single Oral Dose of Thalidomide Enhances the Capacity of Lymphocytes to Secrete Gamma Interferon in Healthy Humans
Verbon, A., Juffermans, N. P., Speelman, P., van Deventer, S. J. H., ten Berge, I. J. M., Guchelaar, H., & van der Poll, T. (2000) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.44.9.2286-2290.2000 · Cited by 56 · see citing works
Clinical Management of Clostridium difficile-Associated Disease
Miller, M. A. (2007) · Clinical Infectious Diseases · doi:10.1086/519257 · Cited by 52 · see citing works
Hospitalizations for Fungal Infections after Initiation of Chronic Dialysis in the United States
Abbott, K. C., Hypolite, I. O., Tveit, D. P., Hshieh, P., Cruess, D. F., & Agodoa, L. Y. C. (2001) · The Nephron journals/Nephron journals · doi:10.1159/000046115 · Cited by 51 · see citing works
Bisphosphonates and jaw osteonecrosis: The UAMS experience
Clarke, B. M., Boyette, J. R., Vural, E. A., Suen, J. Y., Anaissie, E. J., & Stack, B. C. (2007) · Otolaryngology · doi:10.1016/j.otohns.2006.11.008 · Cited by 51 · see citing works
Self-citation
Successful Intermittent Prophylaxis With Trimethoprim/Sulfamethoxazole 2 Days per Week for Pneumocystis carinii (jiroveci) Pneumonia in Pediatric Oncology Patients
Lindemulder, S., & Albano, E. A. (2007) · PEDIATRICS · doi:10.1542/peds.2006-1360 · Cited by 48 · see citing works
Review. Clinical pharmacokinetics of bortezomib.
Levêque, D., Carvalho, M. C. M., & Maloisel, F. (2007) · PubMed · Cited by 47 · see citing works
A study of innate immunity in patients with end-stage renal disease: Special reference to toll-like receptor-2 and -4 expression in peripheral blood monocytes of hemodialysis patients
Kuroki, Y., Tsuchida, K., Go, I., Aoyama, M., Naganuma, T., Takemoto, Y., & Nakatani, T. (2007) · International Journal of Molecular Medicine · doi:10.3892/ijmm.19.5.783 · Cited by 43 · see citing works
Use of prophylactic antifungals in the immunocompromised host
Ship, J. A., Vissink, A., & Challacombe, S. (2007) · Oral Surgery Oral Medicine Oral Pathology Oral Radiology and Endodontology · doi:10.1016/j.tripleo.2006.11.003 · Cited by 43 · see citing works
Risk factors for the development of bacterial infections in multiple myeloma treated with two different vincristine-adriamycin-dexamethasone schedules.
Cesana, C., Nosari, A., Klersy, C., Miqueleiz, S., Rossi, V., Ferrando, P., Valentini, M., Barbarano, L., & Morra, E. (2003) · PubMed · Cited by 41 · see citing works
Iron chelation beyond transfusion iron overload
Pietrangelo, A. (2007) · American Journal of Hematology · doi:10.1002/ajh.21101 · Cited by 38 · see citing works
Changing Patterns of Infections in Patients with Multiple Myeloma
Shaikh, B. S., Lombard, R. M., Appelbaum, P. C., & Bentz, M. S. (2009) · Oncology · doi:10.1159/000225611 · Cited by 38 · see citing works
Antimicrobial Therapy of Clostridium difficile-Associated Diarrhea
Bouza, E., Burillo, A., & Muñóz, P. (2006) · Medical Clinics of North America · doi:10.1016/j.mcna.2006.07.011 · Cited by 36 · see citing works
Update in Tuberculosis 2007
Yew, W. W., & Leung, C. C. (2008) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200710-1561up · Cited by 34 · see citing works
Use of Colony-Stimulating Factors for Chemotherapy-Associated Neutropenia: Review of Current Guidelines
Heuser, M., Ganser, A., & Bokemeyer, C. (2007) · Seminars in Hematology · doi:10.1053/j.seminhematol.2007.04.002 · Cited by 32 · see citing works
Thalidomide–dexamethasone plus pegylated liposomal doxorubicin vs. thalidomide–dexamethasone: a case‐matched study in advanced multiple myeloma
Offidani, M., Bringhen, S., Corvatta, L., Falco, P., Marconi, M., Avonto, I., Piersantelli, M., Polloni, C., Boccadoro, M., Leoni, P., et al. (2007) · European Journal Of Haematology · doi:10.1111/j.1600-0609.2007.00823.x · Cited by 30 · see citing works
Current Patterns of Bacterial Infection in Myelomatosis
Espersen, F., Birgens, H., HERTZ, J. B., & Drivsholm, A. (1984) · Scandinavian Journal of Infectious Diseases · doi:10.3109/00365548409087137 · Cited by 28 · see citing works
Mucormycosis in patients with complicated cirrhosis.
Abbas, Z., Jafri, W., Rasool, S., Abid, S., & Hameed, I. (2007) · PubMed · Cited by 24 · see citing works
Mould-active azoles: pharmacokinetics, drug interactions in neutropenic patients
Gubbins, P. O. (2007) · Current Opinion in Infectious Diseases · doi:10.1097/qco.0b013e3282f1be91 · Cited by 20 · see citing works
Candidaemia in patients with dialysis‐dependent acute renal failure: aetiology, predisposing and prognostic factors
Sung, J., Ko, W., & Huang, J. (2001) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/16.12.2348 · Cited by 18 · see citing works
SEPTICAEMIA IN PATIENTS WITH HAEMATOLOGICAL MALIGNANT DISEASE
KING, K. B. (1980) · The Medical Journal of Australia · doi:10.5694/j.1326-5377.1980.tb135163.x · Cited by 18 · see citing works
Hemophilus influenzae Septicemia and Polyarthritis in Multiple Myeloma
Saba, H. I., Hartmann, R. C., & Herion, J. C. (1979) · Southern Medical Journal · doi:10.1097/00007611-197906000-00032 · Cited by 18 · see citing works
Oral beclomethasone dipropionate: a topically active corticosteroid for the treatment of gastrointestinal graft-versus-host disease following allogeneic hematopoietic cell transplantation
McDonald, G. B. (2007) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.16.10.1709 · Cited by 17 · see citing works
Infection, Immunity, and Hormones/Endocrine Interactions
Khardori, R. K., Adamski, A., & Khardori, N. M. (2007) · Infectious Disease Clinics of North America · doi:10.1016/j.idc.2007.06.002 · Cited by 16 · see citing works
Deep Septic Thrombophlebitis: An Unrecognized Cause of Relapsing Bacteremia in Patients With Cancer
Miceli, M. H., Atoui, R., Thertulien, R., Barlogie, B., Anaissie, E. J., Walker, R. C., & Jones-Jackson, L. B. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.99.289 · Cited by 14 · see citing works
Self-citation
Bortezomib prior to autologous transplant in multiple myeloma: Effects on mobilization, engraftment, and markers of immune function
Uy, G. L., Peles, S., Fisher, N. M., Tomasson, M. H., DiPersio, J. F., & Vij, R. (2006) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2005.11.355 · Cited by 13 · see citing works
Fever of unknown origin (FUO) caused by multiple myeloma: The diagnostic value of the Naprosyn test
Cunha, B. A., Bouyarden, M., & Hamid, N. S. (2006) · Heart & Lung · doi:10.1016/j.hrtlng.2005.10.001 · Cited by 13 · see citing works
Infection – an underappreciated cause of bone pain in multiple myeloma
Desikan, R. K., Bart, B., Sethi, R., Toor, A. A., Spoon, D., Angtuaco, E. E. C., Vanhemert, R., VijayaGopal, A., Singhal, S., Mehta, J., et al. (2003) · British Journal of Haematology · doi:10.1046/j.1365-2141.2003.04178.x · Cited by 10 · see citing works
Self-citation
Treatment of myeloma in patients not eligible for transplantation
Jagannath, S. (2005) · Current Treatment Options in Oncology · doi:10.1007/s11864-005-0007-0 · Cited by 10 · see citing works
Complications of Myeloma Therapy
Dispenzieri, A. A. (2007) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2007.08.002 · Cited by 7 · see citing works
What is the recommended approach to asymptomatic patients who develop a reactive PPD?
Sharma, U., Morris, C. G., & Safranek, S. M. (2006) · PubMed · Cited by 3 · see citing works
The road to cure in multiple myeloma
Ghobrial, I. M., & Anderson, K. C. (2008) · Blood · doi:10.1182/blood-2007-10-116046 · Cited by 3 · see citing works

Flagged first, then by citations

Sorted by citations

Multiple Myeloma
Palumbo, A. P., & Anderson, K. C. (2011) · New England Journal of Medicine · doi:10.1056/nejmra1011442 · Cited by 2,338 · see citing works
Teclistamab in Relapsed or Refractory Multiple Myeloma
Moreau, P., Garfall, A. L., van de Donk, N. W. C. J., Nahi, H., San-Miguel, J. F., Oriol, A., Nooka, A. K., Martin, T., Rosinol, L., Chari, A., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2203478 · Cited by 1,269 · see citing works
Multiple myeloma and infections: a population-based study on 9253 multiple myeloma patients
Blimark, C. H., Holmberg, E. C., Mellqvist, U., Landgren, O., Björkholm, M., Hultcrantz, M. L., Kjellander, C., Turesson, I., & Kristinsson, S. Y. (2014) · Haematologica · doi:10.3324/haematol.2014.107714 · Cited by 525 · see citing works
A phase 1, open-label study of LCAR-B38M, a chimeric antigen receptor T cell therapy directed against B cell maturation antigen, in patients with relapsed or refractory multiple myeloma
Zhao, W., Liu, J., Wang, B., Chen, Y., Cao, X.-M., Yang, Y., Zhang, Y., Wang, F., Zhang, P., Lei, B., et al. (2018) · Journal of Hematology & Oncology · doi:10.1186/s13045-018-0681-6 · Cited by 520 · see citing works
International Myeloma Working Group consensus statement for the management, treatment, and supportive care of patients with myeloma not eligible for standard autologous stem-cell transplantation.
Palumbo, A., Rajkumar, S., Miguel, J. S. S., Larocca, A., Niesvizky, R., Morgan, G., Landgren, O., Hájek, R., Einsele, H., Anderson, K., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.48.7934 · Cited by 385 · see citing works
Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial
Richardson, P. G., Oriol, A., Beksac, M., Liberati, A. M., Galli, M., Schjesvold, F., Lindsay, J., Weisel, K., White, D., Facon, T., et al. (2019) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30152-4 · Cited by 386 · see citing works
European guidelines for primary antifungal prophylaxis in adult haematology patients: summary of the updated recommendations from the European Conference on Infections in Leukaemia
Maertens, J. A., Girmenia, C., Brüggemann, R. J. M., Duarte, R. F., Kibbler, C. C., Ljungman, P. T., Ráčil, Z., Ribaud, P., Slavin, M. A., Cornely, O. A., et al. (2018) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dky286 · Cited by 355 · see citing works
Epidemiological trends in invasive aspergillosis in France: the SAIF network (2005–2007)
Lortholary, O., Gangneux, J.-P., Sitbon, K., Lebeau, B., de Monbrison, F., Le Strat, Y., Coignard, B., Dromer, F., & Bretagne, S. (2011) · Clinical Microbiology and Infection · doi:10.1111/j.1469-0691.2011.03548.x · Cited by 331 · see citing works
Immunogenicity and safety of the adjuvanted recombinant zoster vaccine in adults with haematological malignancies: a phase 3, randomised, clinical trial and post-hoc efficacy analysis
Dagnew, A. F., İlhan, O., Lee, W. S., Woszczyk, D., Kwak, J., Bowcock, S. J., Sohn, S. K., Macias, G. R., Chiou, T.-J., Quiel, D., et al. (2019) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(19)30163-x · Cited by 256 · see citing works
The Expanding Field of Secondary Antibody Deficiency: Causes, Diagnosis, and Management
Patel, S. Y., Carbone, J., & Jolles, S. R. A. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00033 · Cited by 242 · see citing works
Consensus guidelines and recommendations for infection prevention in multiple myeloma: a report from the International Myeloma Working Group
Raje, N. S., Anaissie, E., Kumar, S. K., Lonial, S., Martin, T., Gertz, M. A., Krishnan, A., Hari, P., Ludwig, H., O'Donnell, E., et al. (2022) · The Lancet Haematology · doi:10.1016/s2352-3026(21)00283-0 · Cited by 212 · see citing works
Self-citation
International Myeloma Working Group recommendations for global myeloma care
Ludwig, H., Miguel, J. F. S., Dimopoulos, M. A., Palumbo, A. P., García‐Sánz, R., Powles, R., Lentzsch, S., Chen, W. M., Hou, J., Jurczyszyn, A. J., et al. (2013) · Leukemia · doi:10.1038/leu.2013.293 · Cited by 198 · see citing works
Epidemiology of Infections in Cancer Patients
Zembower, T. (2014) · Cancer treatment and research · doi:10.1007/978-3-319-04220-6_2 · Cited by 196 · see citing works
Analysis of the immune system of multiple myeloma patients achieving long-term disease control by multidimensional flow cytometry
Magalhaes, R. J., Vídriales, M., Paiva, B., Fernández, C., García‐Sánz, R., Mateos, M., Gutierrez, N. C., Lécrevisse, Q., Blanco, J. F., Hernández‐Rivas, J. M., et al. (2012) · Haematologica · doi:10.3324/haematol.2012.067272 · Cited by 172 · see citing works
Self-citation
Monoclonal gammopathy of undetermined significance and risk of infections: a population-based study
Kristinsson, S. Y., Tang, M., Pfeiffer, R. M., Björkholm, M., Goldin, L. R., Blimark, C. H., Mellqvist, U. H., Wåhlin, A., Turesson, I., & Landgren, O. (2011) · Haematologica · doi:10.3324/haematol.2011.054015 · Cited by 146 · see citing works
Myeloid-derived suppressor cells: The green light for myeloma immune escape
Malek, E., Lima, M. J. G. D., Letterio, J. J., Kim, B., Finke, J. H., Driscoll, J. J., & Giralt, S. A. (2016) · Blood Reviews · doi:10.1016/j.blre.2016.04.002 · Cited by 146 · see citing works
Risks, severity and timing of infections in patients with multiple myeloma: a longitudinal cohort study in the era of immunomodulatory drug therapy
Teh, B. W., Harrison, S. J., Worth, L. J., Spelman, T. D., Thursky, K., & Slavin, M. A. (2015) · British Journal of Haematology · doi:10.1111/bjh.13532 · Cited by 129 · see citing works
Expert panel consensus statement on the optimal use of pomalidomide in relapsed and refractory multiple myeloma
Dimopoulos, M. A., Leleu, X. P., Palumbo, A. P., Moreau, P., Delforge, M., Cavo, M., Ludwig, H., Morgan, G. J., Davies, F. E., Sonneveld, P., et al. (2014) · Leukemia · doi:10.1038/leu.2014.60 · Cited by 123 · see citing works
Lenalidomide-Induced Immunomodulation in Multiple Myeloma: Impact on Vaccines and Antitumor Responses
Noonan, K. A., Rudraraju, L., Ferguson, A. K., Emerling, A., Pasetti, M. F., Huff, C. A., & Borrello, I. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-1221 · Cited by 122 · see citing works
Primary prophylaxis of bacterial infections and Pneumocystis jirovecii pneumonia in patients with hematological malignancies and solid tumors
Neumann, S., Krause, S. W., Maschmeyer, G., Schiel, X., & von Lilienfeld‐Toal, M. (2013) · Annals of Hematology · doi:10.1007/s00277-013-1698-0 · Cited by 120 · see citing works
Immunoglobulin Replacement Therapy in Secondary Hypogammaglobulinemia
Compagno, N., Malipiero, G., Cinetto, F., & Agostini, C. (2014) · Frontiers in Immunology · doi:10.3389/fimmu.2014.00626 · Cited by 119 · see citing works
Coinhibitory molecule PD-1 as a potential target for the immunotherapy of multiple myeloma
Atanackovic, D., Luetkens, T., & Kröger, N. M. (2013) · Leukemia · doi:10.1038/leu.2013.310 · Cited by 99 · see citing works
Incidence, timing, and management of infections in patients receiving teclistamab for the treatment of relapsed/refractory multiple myeloma in the MajesTEC‐1 study
Nooka, A. K., Rodriguez, C., Mateos, M., Manier, S., Chastain, K. M., Banerjee, A., Kobos, R., Qi, K., Verona, R. I., Doyle, M., et al. (2023) · Cancer · doi:10.1002/cncr.35107 · Cited by 97 · see citing works
Cancer-Associated Angiogenesis: The Endothelial Cell as a Checkpoint for Immunological Patrolling
Solimando, A. G., Summa, S. D., Vacca, A., & Ribatti, D. (2020) · Cancers · doi:10.3390/cancers12113380 · Cited by 93 · see citing works
Clinical course and risk factors for mortality from COVID‐19 in patients with haematological malignancies
Sánchez‐Pina, J. M., Rodríguez, M., Quismondo, N. C., Gil-Manso, R., Colmenares, R., Gil-Alós, D., Paciello, M. L., Zafra, D., Garcia‐Sanchez, C., Villegas, C., et al. (2020) · European Journal Of Haematology · doi:10.1111/ejh.13493 · Cited by 91 · see citing works
Secondary immunodeficiency in lymphoproliferative malignancies
Friman, V., Winqvist, O., Blimark, C. H., Langerbeins, P., Chapel, H. M., & Dhalla, F. (2016) · Hematological Oncology · doi:10.1002/hon.2323 · Cited by 89 · see citing works
Management of older adults with multiple myeloma
Palumbo, A. P., & Mina, R. (2013) · Blood Reviews · doi:10.1016/j.blre.2013.04.001 · Cited by 85 · see citing works
Subcutaneous immunoglobulins in patients with multiple myeloma and secondary hypogammaglobulinemia: a randomized trial
Vacca, A., Melaccio, A., Sportelli, A., Solimando, A. G., Dammacco, F., & Ria, R. (2017) · Clinical Immunology · doi:10.1016/j.clim.2017.11.014 · Cited by 81 · see citing works
Treatment of relapsed and refractory multiple myeloma in the era of novel agents
van de Donk, N. W. C. J., Lokhorst, H. M., Dimopoulos, M. A., Cavo, M., Morgan, G. J., Einsele, H., Kropff, M. H., Schey, S., Avet‐Loiseau, H., Ludwig, H., et al. (2010) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2010.08.008 · Cited by 75 · see citing works
Cytomegalovirus infection in hematologic malignancy settings other than the allogeneic transplant
Marchesi, F., Pimpinelli, F., Ensoli, F., & Mengarelli, A. (2017) · Hematological Oncology · doi:10.1002/hon.2453 · Cited by 75 · see citing works
A predictive model for risk of early grade ≥ 3 infection in patients with multiple myeloma not eligible for transplant: analysis of the FIRST trial
Dumontet, C., Hulin, C., Dimopoulos, M. A., Belch, A. R., Dispenzieri, A. A., Ludwig, H., Rodon, P., Droogenbroeck, J. V., Qiu, L., Cavo, M., et al. (2018) · Leukemia · doi:10.1038/s41375-018-0133-x · Cited by 73 · see citing works
Management of herpesvirus reactivations in patients with solid tumours and hematologic malignancies: update of the Guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society for Hematology and Medical Oncology (DGHO) on herpes simplex virus type 1, herpes simplex virus type 2, and varicella zoster virus
Henze, L., Buhl, C., Sandherr, M., Cornely, O. A., Heinz, W., Khodamoradi, Y., Kiderlen, T. R., Koehler, P. A., Seidler, A., Sprute, R., et al. (2022) · Annals of Hematology · doi:10.1007/s00277-021-04746-y · Cited by 72 · see citing works
Pain Management in Patients with Multiple Myeloma: An Update
Coluzzi, F., Rolke, R., & Mercadante, S. (2019) · Cancers · doi:10.3390/cancers11122037 · Cited by 70 · see citing works
Characterisation of immunoparesis in newly diagnosed myeloma and its impact on progression-free and overall survival in both old and recent myeloma trials
Heaney, J. L. J., Campbell, J. P., Iqbal, G., Cairns, D. A., Richter, A. G., Child, J. A., Gregory, W. M., Jackson, G. H., Kaiser, M., Owen, R. G., et al. (2018) · Leukemia · doi:10.1038/s41375-018-0163-4 · Cited by 69 · see citing works
Comparative Study of Immune Status to Infectious Agents in Elderly Patients with Multiple Myeloma, Waldenstrom's Macroglobulinemia, and Monoclonal Gammopathy of Undetermined Significance
Karlsson, J., Andréasson, B., Kondori, N., Erman, E., Riesbeck, K., Hogevik, H., & Wennerås, C. (2011) · Clinical and Vaccine Immunology · doi:10.1128/cvi.00021-11 · Cited by 68 · see citing works
Secondary antibody deficiencies
Dhalla, F., & Misbah, S. (2015) · Current Opinion in Allergy and Clinical Immunology · doi:10.1097/aci.0000000000000215 · Cited by 68 · see citing works
Guidelines for screening and management of late and long‐term consequences of myeloma and its treatment
Snowden, J. A., Greenfield, D., Bird, J. M., Boland, E. G., Bowcock, S. J., Fisher, A., Low, E., Morris, M., Yong, K., Pratt, G., et al. (2017) · British Journal of Haematology · doi:10.1111/bjh.14514 · Cited by 69 · see citing works
Monoclonal gammopathy: The good, the bad and the ugly
Glavey, S. V., & Leung, N. (2015) · Blood Reviews · doi:10.1016/j.blre.2015.12.001 · Cited by 66 · see citing works
Immunoglobulin therapy in hematologic neoplasms and after hematopoietic cell transplantation
Ueda, M., Berger, M., Gale, R. P., & Lazarus, H. M. (2017) · Blood Reviews · doi:10.1016/j.blre.2017.09.003 · Cited by 64 · see citing works
Impact of Prophylactic Levofloxacin on Rates of Bloodstream Infection and Fever in Neutropenic Patients with Multiple Myeloma Undergoing Autologous Hematopoietic Stem Cell Transplantation
Satlin, M. J., Vardhana, S. A., Soave, R., Shore, T. B., Mark, T. M., Jacobs, S. E., Walsh, T. J., & Gergis, U. S. (2015) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2015.06.017 · Cited by 62 · see citing works
Update on the optimal use of bortezomib in the treatment of multiple myeloma
Mohan, M., Matin, A., & Davies, F. E. (2017) · Cancer Management and Research · doi:10.2147/cmar.s105163 · Cited by 58 · see citing works
The risk of infections in multiple myeloma before and after the advent of novel agents: a 12-year survey
Brioli, A., Klaus, M., Sayer, H. G., Scholl, S., Ernst, T., Hilgendorf, I., Scherag, A., Yomade, O., Schilling, K., Hochhaus, A., et al. (2019) · Annals of Hematology · doi:10.1007/s00277-019-03621-1 · Cited by 56 · see citing works
Infection risks in multiple myeloma: a systematic review and meta-analysis of randomized trials from 2015 to 2019
Balmaceda, N. B., Aziz, M., Chandrasekar, V. T., McClune, B. L., Kambhampati, S., Shune, L. O., Abdallah, A.-O. A., Anwer, F., Majeed, A., Qazilbash, M. H., et al. (2021) · BMC Cancer · doi:10.1186/s12885-021-08451-x · Cited by 55 · see citing works
Changing treatment paradigms for patients with plasma cell myeloma: Impact upon immune determinants of infection
Teh, B. W., Harrison, S. J., Pellegrini, M., Thursky, K., Worth, L. J., & Slavin, M. A. (2014) · Blood Reviews · doi:10.1016/j.blre.2014.01.004 · Cited by 54 · see citing works
Immune Defects in the Risk of Infection and Response to Vaccination in Monoclonal Gammopathy of Undetermined Significance and Multiple Myeloma
Tete, S. M., Bijl, M., Sahota, S., & Bos, N. (2014) · Frontiers in Immunology · doi:10.3389/fimmu.2014.00257 · Cited by 56 · see citing works
Risk of Invasive Haemophilus influenzae Type b (Hib) Disease in Adults with Secondary Immunodeficiency in the Post-Hib Vaccine Era
Nix, E. B., Hawdon, N., Gravelle, S., Biman, B., Brigden, M. L., Malik, S., McCready, W. G., Ferroni, G., & Ulanova, M. (2012) · Clinical and Vaccine Immunology · doi:10.1128/cvi.05675-11 · Cited by 53 · see citing works
Practical management of adverse events in multiple myeloma: Can therapy be attenuated in older patients?
Palumbo, A. P., Mateos, M., Bringhen, S., & Miguel, J. F. S. (2011) · Blood Reviews · doi:10.1016/j.blre.2011.03.005 · Cited by 51 · see citing works
Viral infection/reactivation during long-term follow-up in multiple myeloma patients with anti-BCMA CAR therapy
Wang, D., Mao, X., Que, Y., Xu, M., Cheng, Y., Huang, L., Wang, J., Xiao, Y., Wang, W., Hu, G., et al. (2021) · Blood Cancer Journal · doi:10.1038/s41408-021-00563-8 · Cited by 51 · see citing works
Incidence and management of adverse events in patients with relapsed and/or refractory multiple myeloma receiving single-agent carfilzomib
Harvey, D. (2014) · Clinical Pharmacology Advances and Applications · doi:10.2147/cpaa.s62512 · Cited by 49 · see citing works
Clinical and Serologic Responses After a Two-dose Series of High-dose Influenza Vaccine in Plasma Cell Disorders: A Prospective, Single-arm Trial
Branagan, A. R., Duffy, E. J., Albrecht, R. A., COOPER, D. L., Seropian, S., Parker, T. L., Gan, G., Li, F., Zelterman, D. A., Boddupalli, C. S., et al. (2017) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2017.02.025 · Cited by 48 · see citing works
Lenalidomide and the risk of serious infection in patients with multiple myeloma: a systematic review and meta-analysis
Li, Y., YinHui, T., Yunliang, Z., & Sun, H. (2017) · Oncotarget · doi:10.18632/oncotarget.16235 · Cited by 47 · see citing works
New Agents in Multiple Myeloma: An Examination of Safety Profiles
Bringhen, S., de Wit, E., & Dimopoulos, M. A. (2017) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2017.05.003 · Cited by 49 · see citing works
The Systemic Cytokine Environment Is Permanently Altered in Multiple Myeloma
Zheng, M. M., Zhang, Z., Bemis, K. D., Belch, A. R., Pilarski, L. M., Shively, J. E., & Kirshner, J. (2013) · PLoS ONE · doi:10.1371/journal.pone.0058504 · Cited by 47 · see citing works
Experience with use of Zostavax® in patients with hematologic malignancy and hematopoietic cell transplant recipients
Naidus, E., Damon, L. E., Schwartz, B. S., Breed, C., & Liu, C. (2011) · American Journal of Hematology · doi:10.1002/ajh.22196 · Cited by 47 · see citing works
Assessment of infection in newly diagnosed multiple myeloma patients: risk factors and main characteristics
Lin, C., Shen, H., Zhou, S., Liu, M., Xu, A., Huang, S., Shen, C., & Zhou, F. (2020) · BMC Infectious Diseases · doi:10.1186/s12879-020-05412-w · Cited by 44 · see citing works
Cumulative Incidence and Relative Risk of Infection in Patients With Multiple Myeloma Treated With Anti-CD38 Monoclonal Antibody-Based Regimens: A Systematic Review and Meta-analysis
Vassilopoulos, S., Vassilopoulos, A., Kalligeros, M., Shehadeh, F., & Mylonakis, E. E. (2022) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofac574 · Cited by 45 · see citing works
High incidence of post‐transplant cytomegalovirus reactivations in myeloma patients undergoing autologous stem cell transplantation after treatment with bortezomib‐based regimens: a survey from the Rome Transplant Network
Marchesi, F., Mengarelli, A., Giannotti, F., Tendas, A., Anaclerico, B., Porrini, R., Picardi, A., Cerchiara, E., Dentamaro, T., Chierichini, A., et al. (2013) · Transplant Infectious Disease · doi:10.1111/tid.12162 · Cited by 44 · see citing works
Targeting NF-κB Signaling for Multiple Myeloma
Wong, A. H.-H., Shin, E. M., Tergaonkar, V., & Chng, W.-J. (2020) · Cancers · doi:10.3390/cancers12082203 · Cited by 42 · see citing works
Hepatitis B virus reactivation in patients with multiple myeloma receiving bortezomib-containing regimens followed by autologous stem cell transplant
Li, J., Huang, B., Li, Y., Zheng, D., Zhou, Z., & Liu, J. (2014) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428194.2014.941833 · Cited by 41 · see citing works
Proteasome inhibitors for the treatment of multiple myeloma
Scalzulli, E., Grammatico, S., Vozella, F., & Petrucci, M. T. (2018) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2018.1441287 · Cited by 41 · see citing works
Challenges in the Role of Gammaglobulin Replacement Therapy and Vaccination Strategies for Hematological Malignancy
Sánchez‐Ramón, S., Dhalla, F., & Chapel, H. M. (2016) · Frontiers in Immunology · doi:10.3389/fimmu.2016.00317 · Cited by 40 · see citing works
Acyclovir Prophylaxis Against Varicella Zoster Virus Reactivation in Multiple Myeloma Patients Treated With Bortezomib-Based Therapies: A Retrospective Analysis of 100 Patients
Swaika, A., Paulus, A., Miller, K. C., Sher, T., Almyroudis, N. G., Ball, D., Wood, M., Masood, A., Lee, K. P., & Chanan-Khan, A. A. (2012) · The Journal of Supportive Oncology · doi:10.1016/j.suponc.2011.10.006 · Cited by 39 · see citing works
Immune dysregulation in multiple myeloma: the current and future role of cell-based immunotherapy
Russell, B. M., & Avigan, D. (2023) · International Journal of Hematology · doi:10.1007/s12185-023-03579-x · Cited by 37 · see citing works
Risk factors associated with early mortality in patients with multiple myeloma who were treated upfront with a novel agents containing regimen
(KMMWP), K. M. M. W. P., Jung, S., Cho, M.-S., Kim, H. K., Kim, S. J., Kım, K., Cheong, J., Kim, S., Kim, J. S., Ahn, J., et al. (2016) · BMC Cancer · doi:10.1186/s12885-016-2645-y · Cited by 38 · see citing works
Inflammation and infection in plasma cell disorders: how pathogens shape the fate of patients
Caro, J., Braunstein, M. J., Williams, L. S., Bruno, B., Kaminetzky, D., Siegel, A., Razzo, B. M., Alfandari, S., Morgan, G. J., Davies, F. E., et al. (2022) · Leukemia · doi:10.1038/s41375-021-01506-9 · Cited by 39 · see citing works
Challenges in microbiological diagnosis of invasive Aspergillus infections
Alanio, A., & Bretagne, S. (2017) · F1000Research · doi:10.12688/f1000research.10216.1 · Cited by 37 · see citing works
Bortezomib: a new player in pre- and post-transplant desensitization?
Lemy, A., Toungouz, M., & Abramowicz, D. (2010) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfq502 · Cited by 37 · see citing works
Infections in haematology patients treated with CAR-T therapies: A systematic review and meta-analysis
Reynolds, G. K., Sim, B., Spelman, T. D., Thomas, A., Longhitano, A., Anderson, M. A., Thursky, K., Slavin, M. A., & Teh, B. W. (2023) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2023.104134 · Cited by 36 · see citing works
Epidemiology and Risks of Infections in Patients With Multiple Myeloma Managed With New Generation Therapies
Lim, C., Sinha, P., Harrison, S. J., Quach, H., Slavin, M. A., & Teh, B. W. (2021) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2021.02.002 · Cited by 36 · see citing works
Cytomegalovirus Reactivation Following Autologous Peripheral Blood Stem Cell Transplantation for Multiple Myeloma in the Era of Novel Chemotherapeutics and Tandem Transplantation
Kim, J. H., Goulston, C., Sanders, S., Lampas, M., Zangari, M., Tricot, G. J. K., & Hanson, K. E. (2012) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2012.06.008 · Cited by 36 · see citing works
Potential therapeutic targets shared between leishmaniasis and cancer
Rashidi, S., Fernández-Rubio, C., Manzano-Román, R., Mansouri, R., Shafiei, R., Ali‐Hassanzadeh, M., Barazesh, A., Karimazar, M., Hatam, G., & Nguewa, P. (2021) · Parasitology · doi:10.1017/s0031182021000160 · Cited by 34 · see citing works
Recent advances in the management of multiple myeloma.
Kumar, L., Verma, R. K., & Radhakrishnan, V. S. (2010) · PubMed · Cited by 34 · see citing works
Natural Killer Cells in the Malignant Niche of Multiple Myeloma
Venglár, O., Bago, J., Motais, B., Hájek, R., & Jelı́nek, T. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2021.816499 · Cited by 33 · see citing works
Lenalidomide use in multiple myeloma (Review)
Zhang, C.-W., Wang, Y., & Ge, X. (2023) · Molecular and Clinical Oncology · doi:10.3892/mco.2023.2705 · Cited by 32 · see citing works
Infectious complications in patients with multiple myeloma treated with new drug combinations containing thalidomide
Offidani, M., Corvatta, L., Polloni, C., Gentili, S., Brioni, A., Visani, G., Galieni, P., Brunori, M., Alesiani, F., Catarini, M., et al. (2011) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428194.2011.555027 · Cited by 30 · see citing works
Systematic review and meta-analysis of recombinant herpes zoster vaccine in immunocompromised populations
Marra, F., Yip, M., Cragg, J. J., & Vadlamudi, N. K. (2024) · PLoS ONE · doi:10.1371/journal.pone.0313889 · Cited by 29 · see citing works
A simple score to predict early severe infections in patients with newly diagnosed multiple myeloma
Encinas, C., Hernández‐Rivas, J., Oriol, A., Rosiñol, L., Blanchard, M. J., Bellón, J. M., García‐Sánz, R., de la Rubia, J., de la Guía, A. L., Ubieto, A. J., et al. (2022) · Blood Cancer Journal · doi:10.1038/s41408-022-00652-2 · Cited by 29 · see citing works
Vaccination in Multiple Myeloma: Review of Current Literature
Alemu, A. W., Richards, J. O., Oaks, M. K., & Thompson, M. A. (2016) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2016.06.006 · Cited by 28 · see citing works
Steroid-Associated Side Effects: A Symptom Management Update on Multiple Myeloma Treatment
King, T., & Faiman, B. M. (2017) · Clinical journal of oncology nursing · doi:10.1188/17.cjon.240-249 · Cited by 29 · see citing works
Incidence of infection according to intravenous immunoglobulin use in autologous hematopoietic stem cell transplant recipients with multiple myeloma
Park, S., Jung, C. W., Jang, J. H., Kim, S. J., Kim, W. S., & Kım, K. (2015) · Transplant Infectious Disease · doi:10.1111/tid.12424 · Cited by 28 · see citing works
Management of secondary immunodeficiency in hematological malignancies in the era of modern oncology
Shah, N. D., Mustafa, S. S., & Vinh, D. C. (2022) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2022.103896 · Cited by 27 · see citing works
The Impact of Hyperglycemia on Risk of Severe Infections during Early Period of Induction Therapy in Patients with Newly Diagnosed Multiple Myeloma
Jung, S., Jang, H., Lee, S.-S., Ahn, J., Yang, D., Kim, Y., Kim, H., & Lee, J. (2014) · BioMed Research International · doi:10.1155/2014/413149 · Cited by 28 · see citing works
Incidence of neutropenia and use of granulocyte colony-stimulating factors in multiple myeloma: is current clinical practice adequate?
Leleu, X. P., Gay, F., Flament, A., Allcott, K., & Delforge, M. (2017) · Annals of Hematology · doi:10.1007/s00277-017-3191-7 · Cited by 28 · see citing works
Prevention of infections including vaccination strategies in multiple myeloma
Ludwig, H., & Kumar, S. K. (2022) · American Journal of Hematology · doi:10.1002/ajh.26766 · Cited by 27 · see citing works
Management of older patients with multiple myeloma
Gay, F., & Palumbo, A. P. (2011) · Blood Reviews · doi:10.1016/j.blre.2010.10.003 · Cited by 25 · see citing works
Non-osseous incidental findings in low-dose whole-body CT in patients with multiple myeloma
Surov, A., Bach, A. G., Tcherkes, A., & Schramm, D. (2014) · British Journal of Radiology · doi:10.1259/bjr.20140185 · Cited by 24 · see citing works
Viral infections in the biologic therapy era
Noreña, I., Fernández‐Ruiz, M., & Aguado, J. M. (2018) · Expert Review of Anti-infective Therapy · doi:10.1080/14787210.2018.1521270 · Cited by 24 · see citing works
Therapy of Relapsed and Refractory Multiple Myeloma
Moehler, T. M., & Goldschmidt, H. (2011) · Recent results in cancer research/Recent Results in Cancer Research · doi:10.1007/978-3-540-85772-3_11 · Cited by 24 · see citing works
Patients With Multiple Myeloma Have More Complications After Surgical Treatment of Hip Fracture
Park, K. J., Menendez, M. E., Mears, S. C., & Barnes, C. L. (2016) · Geriatric Orthopaedic Surgery & Rehabilitation · doi:10.1177/2151458516658330 · Cited by 24 · see citing works
Adverse event management in patients with relapsed and refractory multiple myeloma taking pomalidomide plus low‐dose dexamethasone: A pooled analysis
Moreau, P., Dimopoulos, M. A., Richardson, P. G. G., Siegel, D. S. D., Cavo, M., Corradini, P., Weisel, K. C., Delforge, M., O’Gorman, P., Song, K., et al. (2017) · European Journal Of Haematology · doi:10.1111/ejh.12903 · Cited by 24 · see citing works
Common community‐acquired infections and subsequent risk of multiple myeloma: A population‐based study
McShane, C. M., Murray, L., Engels, E. A., Landgren, O., & Anderson, L. A. (2013) · International Journal of Cancer · doi:10.1002/ijc.28479 · Cited by 24 · see citing works
Lymphocytopenia is associated with an increased risk of severe infections in patients with multiple myeloma treated with bortezomib-based regimens
Jung, S., Bae, S.-Y., Ahn, J., Kang, S., Yang, D., Kim, Y., Kim, H., & Lee, J. (2013) · International Journal of Hematology · doi:10.1007/s12185-013-1270-7 · Cited by 24 · see citing works
INVASIVE FUNGAL INFECTIONS IN PATIENTS WITH CHRONIC LYMPHOPROLIFERATIVE DISORDERS IN THE ERA OF TARGET DRUGS
Pagano, L., & Facchinelli, D. (2018) · Mediterranean Journal of Hematology and Infectious Diseases · doi:10.4084/mjhid.2018.063 · Cited by 23 · see citing works
Cellular Immune Response after Vaccination in Patients with Cancer—Review on Past and Present Experiences
Rüthrich, M. M., Giesen, N., Mellinghoff, S. C., Rieger, C. T., & von Lilienfeld‐Toal, M. (2022) · Vaccines · doi:10.3390/vaccines10020182 · Cited by 23 · see citing works
Cytomegalovirus reactivation in patients with multiple myeloma
Hasegawa, T., Aisa, Y., Shimazaki, K., Ito, C., & Nakazato, T. (2015) · European Journal Of Haematology · doi:10.1111/ejh.12551 · Cited by 23 · see citing works
Advances in Supportive Care for Multiple Myeloma
Raje, N. S., Yee, A. J., & Roodman, G. D. (2014) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2014.0055 · Cited by 22 · see citing works
Risk factors for severe infections in secondary immunodeficiency: a retrospective US administrative claims study in patients with hematological malignancies
Jolles, S. R. A., Smith, B. D., Vinh, D. C., Mallick, R., Espinoza, G., DeKoven, M., & Divino, V. M. (2021) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2021.1992761 · Cited by 22 · see citing works
Melphalan: Recent insights on synthetic, analytical and medicinal aspects
Pahwa, R., Chhabra, J., Kumar, R., & Narang, R. (2022) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2022.114494 · Cited by 22 · see citing works
Effect of levofloxacin prophylaxis for prevention of severe infections in multiple myeloma patients receiving bortezomib-containing regimens
Jung, S., Kang, S., Jang, H., Ahn, J., Yang, D., Lee, S.-S., Kim, Y., Kim, H., & Lee, J. (2014) · International Journal of Hematology · doi:10.1007/s12185-014-1672-1 · Cited by 22 · see citing works
Cytomegalovirus infection in patients with haematological diseases and after autologous stem cell transplantation as consolidation: a single-centre study
Piukovics, K., Terhes, G., Pálfi, T. G., Bereczki, Á., Rárosi, F., Deák, J., Borbényi, Z., & Urbán, E. Z. (2016) · Annals of Hematology · doi:10.1007/s00277-016-2831-7 · Cited by 22 · see citing works

Anaissie E. Infections in patients with multiple myeloma. Semin Hematol
Nucci, M., & Anaissie, E. (2016)
Self-citation
Multiple Myeloma and Risk of Infection
Hamed, N. A. M. (2024) · Cancer therapy & Oncology International Journal · doi:10.19080/ctoij.2024.27.556216
Infections in Patients with Multiple Myeloma in the Era of Novel Agents and Stem Cell Therapies
Al-Jasser, A. M., & Al‐Anazi, K. A. (2019) · IntechOpen eBooks · doi:10.5772/intechopen.81683 · Cited by 5 · see citing works
The risk of infections in multiple myeloma before and after the advent of novel agents: a 12-year survey
Brioli, A., Klaus, M., Sayer, H. G., Scholl, S., Ernst, T., Hilgendorf, I., Scherag, A., Yomade, O., Schilling, K., Hochhaus, A., et al. (2019) · Annals of Hematology · doi:10.1007/s00277-019-03621-1 · Cited by 56 · see citing works
Multiple myeloma and infections in the era of novel treatment modalities
Akhmedov, M., Zeynalova, P. A., & Феденко, А. А. (2024) · Leukemia Research · doi:10.1016/j.leukres.2024.107544 · Cited by 5 · see citing works

Authors: Nucci, M., & Anaissie, E.
Affiliations: University of Arkansas for Medical Sciences (US)
Venue: Clinical Infectious Diseases
Publisher: Oxford University Press (OUP)
Published: 2009-10-15
Volume: 49
Issue: 8
Pages: 1211-1225
ISSN: 1058-4838 (ISSN-L)
1537-6591
DOI: 10.1086/605664
OpenAlex: W1978643311
Cited by: 347
References: 118
Citations by year: 2026: 8 · 2025: 14 · 2024: 17 · 2023: 21 · 2022: 31 · 2021: 22 · 2020: 25 · 2019: 28 · 2018: 25 · 2017: 22 · 2016: 28 · 2015: 16 · 2014: 28 · 2013: 21 · 2012: 13
FWCI: 9.08
Type: journal article
Language: en
Open access: closed
Locations: Clinical Infectious Diseases (publishedVersion)
PubMed (publishedVersion)
Topics: Health Sciences › Medicine › Hematology › Multiple Myeloma Research and Treatments
Health Sciences › Medicine › Oncology › Neutropenia and Cancer Infections
Health Sciences › Medicine › Infectious Diseases › Antifungal resistance and susceptibility
Keywords: multiple myeloma, infection risk, immunosuppression, high-dose therapy, stem cell transplantation, bortezomib, thalidomide, lenalidomide, herpes zoster reactivation, herpes simplex virus, Clostridium difficile, cytomegalovirus, infection control
MeSH terms: Antineoplastic Agents, Bacterial Infections, Humans, Multiple Myeloma, Mycoses, Risk Factors, Virus Diseases, Immunocompromised Host, Stem Cell Transplantation

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Infections in Patients with Multiple Myeloma in the Era of High‐Dose Therapy and Novel Agents

Abstract

Integrity signals

Claims the paper makes

Claims other papers make about this one

Cites

Cited by

Related

Record

About these checks